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Fibromyalgia (FM) is a disabling syndrome characterized by chronic pain associated with fatigue. Its 
pathogenesis is unknown, but alterations in central sensitization, involving an imbalance of brain-
derived neurotrophic factor (BDNF) and inflammatory biomarkers, appear to be implicated. The aim 
of this study was to evaluate the impact of attachment-based compassion therapy (ABCT) on levels 
of BDNF, the inflammatory markers TNF-α, IL-6, IL-10, and the C-reactive protein (CRP), analysing 
whether biomarkers play a mediating/moderating role in improvements in FM functional status. Thirty-
four female patients with FM participated in a RCT and were assigned to ABCT or relaxation therapy. 
Blood extractions were conducted at baseline and post-intervention, with self-report assessments 
of functional status (FIQ) at baseline, post-intervention and 3-month follow-up. A pro-inflammatory 
composite was obtained by summing up IL-6, TNF-α and CRP normalized values. Non-parametric 
tests, analysis of variance and regression models were used to evaluate treatment and mediation/
moderation. Compared to relaxation therapy, ABCT showed significant improvements in FIQ and 
decreases in BDNF, CRP, and pro-inflammatory composite. Changes in BDNF had a mediating role 
in FIQ. ABCT seems to reduce BDNF and appears to have anti-inflammatory effects in FM patients. 
Reductions in BDNF could be a mechanism of FM functional status improvement.
Clinical Trial Registration: http://ClinicalTrials.gov, identifier NCT02454244. Date: May 27th, 2015.
Fibromyalgia (FM) is a debilitating rheumatic chronic pain syndrome of unknown and complex aetiology, which 
includes symptoms such as widespread pain, fatigue, disturbed sleep, cognitive difficulties, psychological distress 
and associated affective disorders1–3. Its pathogenesis is not clearly understood, and, up to now, no curative treat-
ment for this condition has been found4. The central nervous system (CNS) might play a leading role5, involving 
possible altered pain pathways in the form of central sensitizations and abnormal amplifications of pain4,6. It has 
been said that ongoing peripheral nociceptive input seems to be important to maintain central sensitization7. In 
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this sense, FM has been related to a variety of physical and/or psychological stressors, which may contribute to a 
chronic pro-inflammatory state (both in the CNS and in peripheral tissues), which in turn could also exert effects 
in central processing of pain8. These possible altered pain pathways might involve low-grade baseline chronic 
neuro-inflammation processes, with stress peptides triggering the release of neurosensitizing mediators9.
Several biological mechanisms have been proposed in the development of the altered state in FM. Among oth-
ers, higher levels of pro-inflammatory cytokines (e.g. interleukin IL-6 and Tumour Necrosis Factor or TNF-α) as 
well as lower levels of anti-inflammatory cytokines (e.g. interleukin IL-10) have been consistently observed in the 
central sensitized state of FM8,10–12. In general, it has been argued that an imbalance of pro- and anti-inflammatory 
cytokines could lead to a chronic inflammatory status in the CNS and the peripheral nervous system ‒ i.e. 
neuro-inflammation ‒ thus facilitating the sensitization of peripheral nerves to nociceptive stimuli8,11. Moreover, 
cytokines also affect neurotransmitters in the CNS involved in the experience of pain13 as well as the prolonging 
of other FM-related symptoms, such as fatigue, sleep problems, cognitive disturbances, and affective disorders8,13. 
Levels of C-reactive protein (CRP) have also been found to be higher in FM patients14. CRP is an acute phase pro-
tein elevated in inflammatory contexts stimulated by cytokines15, and it has been significantly correlated with IL-6 
levels, reinforcing the idea that inflammation may contribute to FM symptoms14. In addition, positive correlations 
between increased brain-derived neurotrophic factor (BDNF) and S100B protein levels ‒ which are associated 
with the coexistence of central sensitivity and lower pressure pain thresholds in FM ‒ have recently been identi-
fied16. BDNF is known to play a key role in a variety of neuroplasticity processes, including pain modulation, pain 
transduction, nociception, and hyperalgesia17, all of which are altered in FM. Plasma levels of BDNF have also 
been found to be increased in patients with fibromyalgia18. Thus, BDNF provides a possible promising first step 
towards the development of new diagnostics of FM based on biomarkers19. In summary, an imbalance of pro- and 
anti- inflammatory cytokines as well as higher levels of CRP and BDNF have been observed in the plasma and/or 
serum of FM patients4,8,12. It has been proposed that the baseline pro-inflammatory status of chronic pain patients 
might have a moderating role on treatment improvements. Specifically, higher pre-treatment levels of IL-6 and 
TNF- α have been found to be associated with reduced improvement in pain intensity and other psychological 
health-related outcomes, providing a possible explanation of the heterogeneity in treatment response20.
The absence of consensus for curative treatments of FM21 and its large presence in the general population ‒ 
with global prevalence values of approximately 2.7%4 ‒ together with resulting unemployment, number of days 
of absenteeism from work and incapacity benefits claimed22 has motivated a large amount of research in this area. 
Few pharmacological treatments have demonstrated a significant impact on multiple FM symptom domains, 
but non-pharmacologic interventions ‒ e.g. psychological cognitive behavioural therapy ‒ have demonstrated 
multidimensional effects23. That is why, in the last few years, so-called “third-wave psychological interventions”, 
which seek to activate values and foster interpersonal virtues such as compassion, forgiveness and gratitude24, 
have been an object of special focus and attention25. For instance, Montero-Marin et al.26 recently found that a 
new third-wave psychological treatment, attachment-based compassion therapy (ABCT) ‒ which is composed 
of a regimen of 8 sessions of 2 hours of mindfulness and compassion practices ‒ administered as coadjutant 
treatment along with standard of care, improved in a significant and clinically relevant way the general health 
status of patients with FM compared to a suitable active control group of relaxation therapy. So far, there is some 
evidence of the regulation of and changes in the levels of inflammatory cytokines and in the expression of the 
corresponding genes as a result of mindfulness practices in distinct populations, including experienced medita-
tors27–30, suggesting that the regulation of inflammatory pathways may configure some of the mechanisms under-
lying the therapeutic potential of this type of interventions. However, no studies have investigated the influence of 
the specific ABCT programme ‒ which also adds compassion practices ‒ on BDNF and low-grade inflammation 
level of FM patients.
With this background, the main aim of the present exploratory study was to extend previous clinical findings 
reported by Montero-Marin et al.26 by analysing the possible influence of ABCT (vs relaxation therapy) on the 
levels of BDNF and CRP and on the levels of IL-6, TNF-α and IL-10 cytokines in patients suffering from FM. In 
addition, we also aimed to analyse whether the referenced biomarkers play a mediating and/or a moderating role 
on clinical improvements in the FM functional status. Our general exploratory hypotheses where that: a) ABCT 
would result in significantly greater decreases in the BDNF and pro-inflammatory markers as well as significantly 
greater increases in the anti-inflammatory markers compared with the relaxation condition; and b) BDNF and 
(pro- and anti-) inflammatory biomarkers would play a significant mediating and moderating role on clinical 
improvements in the FM functional status.
Method
A parallel randomized controlled clinical trial (RCT) design was used. Through two arms (ABCT vs relaxation 
therapy) and pre-treatment, post-treatment, and 3-month follow up assessments, the present work reports sec-
ondary data that form part of a larger study26 examining the efficacy of ABCT in the treatment of FM patients 
(TrialTrials.gov Registration: NCT02454244). Findings from a third treatment arm outlined in the protocol that 
used mindfulness plus amygdala retraining will be reported elsewhere.
Procedure. Study participants were recruited from eight primary health-care centres in the city of Zaragoza, 
Spain. The present study inclusion criteria were: (1) male or female aged between 18 and 65 years, (2) able to read 
and understand Spanish, and (3) diagnosed with FM criteria (ACR 1990) by a rheumatologist working for the 
Spanish National Health Service (SNHS). The exclusion criteria were: (1) aged <18 or>65 years, (2) presence of 
a severe Axis I psychiatric/somatic disorder, autoimmune disease, or use of corticosteroid medication, and (3) 
current participation in another clinical trial. Other medication use was permitted as part of standard care as long 
as the participant agreed not to change the dosage during the study period.
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General practitioners (GPs) identified potential participants who were then interviewed at the same clinic by 
an independent researcher until the required sample size was achieved. Those patients who met the inclusion/
exclusion criteria and gave their written informed consent before the baseline assessment were included in the 
study and randomized. A researcher who had no involvement in the study generated a simple random alloca-
tion sequence by using computer software to determine group assignment. Randomization was implemented 
via telephone, and the allocation details were concealed from the other researchers involved until all participants 
had been assigned. Participants were not informed of group allocation until after completion of baseline assess-
ments, and they were not informed which allocation condition was the target intervention. The outcome assessor 
remained blind as to participant allocation.
Informed consent was obtained from February to April 2015, randomization occurred in April 2015, inter-
ventions were delivered from May to October 2015, and follow-up measurements were collected from October 
2015 to March 2016. The RCT was conducted according to the “Initiative on Methods, Measurement and Pain 
Assessment in Clinical Trials” (IMMPACT) recommendations and the “Consolidated Standards of Reporting 
Trials” (CONSORT) guidelines. The study protocol was approved by the ethical review board of the regional 
health authority of Aragon (CEICA), Spain (PI15/0049; 01/04/2015). A more detailed explanation of the proce-
dure is published elsewhere26.
Participants. Sample size estimation for the RCT primary outcome of FM functional status (Fibromyalgia 
Impact Questionnaire, ‒ FIQ) was based on a clinically relevant expected difference of at least 20%. A previous 
study with similar features found a FIQ mean and SD of 70.8 and 15.2, respectively31. Therefore, a difference of 
14.6 points between groups was our target (which is equivalent to 0.95 SDs). To detect this difference with a 5% 
significance level and 80% statistical power in a two-tailed test, we needed 18 participants per group. We expected 
a dropout rate of approximately 20%, so we increased the numbers to reach an initial total sample size of 42 
subjects.
Finally, a total of 34 FM patients (ABCT: n = 19; relaxation: n = 15) who completed all of the biomarker meas-
urement tests were included in the present study. The distributions of socio-demographic and clinical character-
istics of participants at baseline for each group are shown in Table 1. Participants were all female, in their early 
fifties, mostly with partner, and dwelling in their own home in an urban residence. They were roughly equally 
distributed among primary, secondary and university education levels, and the majority were in sick-leave/disa-
bility, with a median income level of 1–2 minimum inter-professional salaries ‒ MIS − (Q1 = <MIS − Q3 = 2–4 
MIS). In clinical terms, participants presented a mean of FM symptoms above the average of FM patients [FIQ: 
Mn = 63.91 (SD = 18.09)]. They had been suffering from FM for a mean of 40 months (SD =30.64), they visited 
mental health services a median of 2 times during the previous year (Q1 = 0 − Q3 = 8), and 30 of them were taking 
FM-related medication (88.2%). There were no significant differences between groups in any of the referenced 
variables (Table 1).
Treatments. Both ABCT and relaxation were presented as suitable active interventions and included 8 
weekly 2-hour sessions and 3 monthly booster sessions (2 hours each) that were combined with treatment as 
usual (TAU) provided by the SNHS for FM patients. TAU was offered by the corresponding general practitioner 
and consisted of administering drugs for pain as well as antidepressants ‒ it could also include pharmacological 
treatments for insomnia and fatigue. Daily homework assignments with specific exercises (i.e. meditation or 
relaxation) were recommended.
Attachment-based compassion therapy (ABCT). The ABCT training program32 was especially adapted for FM 
patients26. In general, this intervention involved exercises of mindfulness and visualizations focused on augment-
ing the patients’ ability to be considerate and kind towards themselves as well as others’ experiences when facing 
suffering. Specifically, ABCT includes exercises of mindfulness breathing, compassionate body scan, connecting 
with affection and compassion with others, replacing the inner critical voice with a more tolerant one, awareness 
of the ability to receive affection and of one’s own capacity to give affection and forgiveness and to manage envy 
and others’ suffering in difficult relationships, equanimity and gratitude.
Relaxation therapy. The relaxation arm constituted a low-intensity and non-specific but suitable active control 
condition that included different relaxation techniques26, such as guided relaxation through imagery, relaxation 
through landscape visualizations, working with emotions through imagination, autogenic training by imagining 
a ball of light with sensations of heat and body sweeping heaviness to facilitate relaxation, progressive muscle 
relaxation by tensing and relaxing the muscles to become aware of the different sensations and to reach relaxation, 
and different breathing exercises, such as slow and deep inspiration and exhalation to calm anxiety26,33.
Study measures. Participants completed a socio-demographic paper-and-pencil survey at baseline that 
included: age, sex, marital status (in a stable relationship vs not in a stable relationship), dwelling (homeowner vs 
renter), place of residence (urban vs non-urban), education (Primary, High school, University), employment sta-
tus (looking after the family/home, employed, sick leave/disabled, unemployed), and income level (less than min-
imum inter-professional salary or <MIS, 1‒2 MIS, 2‒4 MIS, >4 MIS). Information was collected on the number 
of months participants had suffered from FM, the number of visits to mental health services during the last year, 
whether they were taking FM-related medication during the last year and which ones (analgesics, NSAIDs, anx-
iolytics, opiates, antidepressants, hypnotics, and anticonvulsants), the credibility of their intervention (on a scale 
from 0 to 10), and their treatment preference (ABCT, relaxation, other, indifferent).
The Fibromyalgia Impact Questionnaire (FIQ)34, which is the gold-standard measure of functional status in FM 
patients, was carried out at baseline, post-treatment and 3-month follow up as the primary outcome measure of 
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the trial. It is a self-report measure based on 10 items that were developed to capture a broad spectrum of prob-
lems and difficulties related to FM (e.g. ability to perform physical activities, subjective feelings, work ability, pain, 
fatigue, morning tiredness, stiffness, anxiety, and depression). It is considered to be a primary efficacy end-point 
measure of response to therapy, and it is scaled from 0 to 100, with higher scores indicating greater functional 
impairment. The FIQ has demonstrated good psychometric properties in its Spanish validation35.
Participants were scheduled for blood extraction prior to treatment (forming part of the baseline evaluation) 
and some days after treatment (post-treatment evaluation, which was within 5 days following treatment in all of 
cases). To minimize circadian variability in immunological markers, all blood samples were collected between 
8:00–8:30 AM after night fasting. After extraction, blood was centrifuged and serum was frozen to −80 °C until 
the analyses at LABCO laboratories, where BDNF was analysed with ELISA (R&D systems©), IL-6, TNF-α, and 
IL-10 with Immulite© 1000 (Siemens), and CRP with immunoturbidimetry (CRP Beckman Coulter©). The kits 
were used, and the levels of biomarkers calculated according to the manufacturer instructions. The parallel design 
of the study ensured that the groups would display equivalent seasonal variability.
Statistical analyses. We used means (SD), medians (interquartile range), and frequencies (percentages) 
to describe the distribution of baseline characteristics across arms according to the nature of each variable ‒ the 
corresponding t-test, Mann-Whitney U, and Fisher exact probability test were used for comparisons between the 
ABCT and relaxation groups.
All outcome measures were evaluated for normality with the Kolmogorov-Smirnov test. Concentrations of 
cytokines and CRP measures were subjected to a natural logarithmic transformation to normalize the signifi-
cantly skewed data distributions (FIQ and BDNF showed a normal distribution, so they were always analysed 
without transformation). In addition, to obtain a general view of the inflammatory status, a composite index score 
Variables
ABCT 
(n = 19)
Relaxation 
(n = 15) p
Socio-demographic
Age, mean (SD) 52.63 (7.76) 53.60 (5.08) 0.679
Sex female, n (%) 19 (100) 15 (100) 1.00
Stable relationship, n (%) 16 (84.2) 11 (73.3) 0.672
Homeowner, n (%) 18 (94.7) 14 (93.3) 0.999
Urban residence, n (%) 15 (84.2) 15 (100) 0.113
Education level, n (%)
0.123
  Primary school 9 (47.3) 2 (13.4)
  High school 6 (31.6) 8 (53.3)
  University 4 (21.1) 5 (33.3)
Employment status, n (%)
0.349
  Looking after the family/home 7 (36.8) 3 (20.0)
  Employed 1 (5.3) 4 (26.6)
  Sick leave/disabled 9 (47.4) 7 (46.7)
  Unemployed 2 (10.5) 1 (6.7)
Income level, median (Q1‒Q3)
1-2 MIS 1-2 MIS
0.851(<MIS ‒ 2-4 
MIS)
(1-2 MIS ‒ 1-2 
MIS)
Clinical variables
Fibromyalgia (FIQ), mean (SD) 67.31(17.17) 61.12 (20.21) 0.341
  Range (0-100)
Months with FM symptoms, mean (SD) 40.40 (29.00) 43.13 (33.20) 0.800
Visits to MHS last year, median (Q1‒Q3) 2 (0–11) 1 (0–4) 0.560
On medication last year, n (%) 18 (94.7) 12 (80.0) 0.299
Type of medication last year, n (%)
  Analgesics* 6 (31.6) 4 (26.7) 0.999
  NSAIDs 7 (36.8) 3 (20.0) 0.451
  Anxiolytics 5 (26.3) 7 (46.7) 0.288
  Opiates 8 (42.1) 3 (20.5) 0.271
  Antidepressants 10 (52.6) 8 (53.3) 0.999
  Hypnotics 4 (21.1) 0 (0.0) 0.113
  Anticonvulsants 6 (31.6) 3 (20.0) 0.697
Table 1. Characteristics of participants at baseline. Note: Means with standard deviations (SD), medians with 
interquartile range, or number of cases with percentages (%) for each group are presented where appropriate. 
MIS: minimum inter-professional salary. MHS: mental health services. *Painkillers in a broad sense, including 
triptans or anti-migraine drugs (e.g. Paracetamol, Metamizole, Sumatriptan, Rizatriptan).
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(General Inflammation ‒ GI composite) integrating those biomarkers that are theoretically of pro-inflammatory 
type8,15 was calculated by adding the corresponding Z scores for the normalized IL-6, TNF-α and CRP values. 
This inflammation score allows for the calculation of an aggregate index of all pro-inflammatory biomarkers 
by converting them to a comparable score and then totalling the values for each individual36. This procedure 
was contrasted by a principal-component analysis of the referred established measures of pro-inflammatory 
activity8,15, identifying one single factor at pre-test (accounting for 44% of the variance, with the factor load-
ings of IL-6 = 0.70, TNF-α = 0.62, and CRP = 0.68) and at post-test (43% of the variance, with the loadings of 
IL-6 = 0.76, TNF-α = 0.51, and CRP = 0.69). In this context, a composite index takes advantage of the predictive 
value of the three pro-inflammatory measures considered while minimizing measurement errors of the single 
components37, so the use of that index was chosen. Previous studies have designed and used similar compre-
hensive indices of inflammation that combine some interleukins and/or other biomarkers of inflammation plus 
CRP36–38.
First, we examined the effect of ABCT compared with the relaxation condition on FM functional status (FIQ) 
and all of the biomarker variables by an intention-to-treat basis and using the non-parametric Mann-Whitney U 
test to compare the two groups on the raw (not log-transformed) delta-values (change scores). Violin plots repre-
senting both information pertaining to the summary statistics of the data set as well as the density of data points 
throughout the range of the raw data set were used to represent treatment effects. After carrying out log transfor-
mations (where necessary), we also conducted repeated measures (RM) ANOVAs to introduce the possibility of 
calculating partial eta squared effect sizes measures (ƞ2) and ANCOVAs at post-treatment (and at follow up on 
FIQ), with the baseline as a covariate, to gain statistical power and increase confidence in our conclusions39,40. 
Partial eta squared is interpreted as follows: ƞ2 ≤ 0.01 are small, ƞ2 = 0.06 are intermediate, and ƞ2 ≥ 0.14 are 
large41. Descriptive statistics (Means and SDs) and the percentages of pre-post increment (Δ%) of biomarkers 
were also calculated.
Following Judd, Kenny & McClelland42, the potential mediating and moderating effects of biomarkers on the 
FM functional status were evaluated using the total group of participants as a within-subjects design to achieve 
a more powerful analysis by regressing the FM functional status pre‒follow up difference on the biomarker pre‒
post difference and sum using ordinary least squares (OLS) regression models. This approach proposes a test of 
mediation and moderation for designs where the same individuals are measured on distinct time points, includ-
ing assessments of the mediator/moderator and the dependent variable. It is applicable whenever observations 
are non-independent of each other because they come from the same participant, and it includes designs in which 
the factor that causes the dependence is crossed with the independent variable, which is the repeated-measures 
factor. In these conditions, it is proposed that mediation is indicated when the difference in the dependent var-
iable depends on the difference in the mediator/moderator, whereas moderation is indicated if the difference in 
the dependent variable depends on the sum of the mediator/moderator variable42. Other works have explored 
the analysis of mediation/moderation in within-subjects designs using change scores43,44, but the Judd et al. 
approach42 has been widely used and applied in previous research45–54 because it is the dominant method for 
assessing mediation/moderation in within-subjects designs55, and it has even been referred to as an important 
and valuable contribution by authors from other different analytical perspectives56.
Nevertheless, to facilitate the understanding of readers and to produce a more powerful analysis based on 
an indirect effect test using a bootstrapped confidence interval, we used the path analysis framework that was 
recently developed for within-subjects designs by Montoya & Hayes55 from the Judd et al. approach42. For that, we 
explored the indirect relationships among the repeated-measures factor, the biomarker pre‒post difference and 
sum and the FM functional status pre‒follow up difference, using OLS analysis with unstandardized path esti-
mates from regression coefficients, where: (i) the repeated-measures factor was the independent variable (“X”), 
(ii) the biomarker pre‒post difference (M1) and sum (M2) were the mediating and moderating factors respectively, 
and (iii) the FM functional status pre‒follow up difference was the dependent variable (Y). We introduced the 
centred biomarker sum to assess the residual FM functional status over and above the mediating effect by means 
of the intercept42,55 as follows: Y = c′ + b (M1) + d [(M2) − (mean M2)] + e; where c′, b and d are the regression 
intercept and slopes respectively, and e denotes the error in estimation. A generic path diagram of a mediation/
moderation within-subjects design from the proposal of Judd et al.42 and the development of Montoya & Hayes55 
can be observed in Fig. 1. Beta coefficients (β) were used to assess the individual contribution of the biomarker 
pre‒post difference and sum as predictors to explain the FM functional status pre‒follow up difference, and the 
Wald test was used to evaluate their statistical significance. Additionally, the FM functional status pre‒follow 
up difference was regressed using the stepwise method on the pre‒post difference scores of all biomarkers that 
showed possible mediating effects in the Judd et al. formulation42 (b significant in Fig. 1). The regression coeffi-
cient for bootstrapped indirect effects was calculated, as was its 95% confidence interval (95% CI). This test can be 
applied to small samples to overcome possible problems of asymmetry in the distribution of the indirect effects57, 
which are statistically significant when the 95% CI of the corresponding “a x b” parameter does not include zero. 
Multiple determination coefficients (R2) were calculated to observe the explanatory power of the regression mod-
els. Finally, tolerance (T) and variance inflation factor (VIF) were calculated to evaluate the degree of collinearity 
among possible mediators. Values of T < 0.10 and VIF > 10 represent unacceptable levels of T and VIF 58.
The overall α level for the primary outcome analyses of FM functional status (FIQ) ‒ which presented three 
possible comparisons, as was registered in ClinicalTrials.gov (NCT02454244) and published in a previous paper26 
‒ was set at0.05 using two-tailed tests and Bonferroni’s multiple comparisons criterion. However, in the present 
secondary analysis of biomarkers, we did not make an adjustment for multiple tests by means of Bonferroni 
correction. This adjustment is usually used assuming that all tests are independent of each other. However, in 
some practical applications, such as in this case, that is often not maintainable. In addition, it is well-known that 
Bonferroni correction can be too conservative, causing a high rate of false negatives, which in turn contributes 
to publication bias59. Thus, considering all of the above and keeping in mind that the present work is a secondary 
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analysis of a very exploratory nature60, no corrections for multiple measurements were used for the biomarker 
outcomes.
Statistical analyses were carried out using the IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: 
IBM Corp.
Ethical approval. The study was approved by the ethical review board of the regional health authority, 
Aragon Ethical Committee (CEICA), Spain (PI15/0049; 01/04/2015). All procedures performed in this study 
involving human participants were in accordance with the ethical standards of the institutional research commit-
tee (Aragon Ethical Committee, CEICA), the 1964 Helsinki Declaration and its later amendments or comparable 
ethical standards, and the Declaration of Madrid of the World Psychiatric Association and Uniform Requirements 
for Manuscripts Submitted to Bio-Medical Journals. Informed consent was obtained from all individual partici-
pants included in the study.
Results
The study flowchart is provided in Fig. 2. Of the 83 patients who were eligible for screening, 19 were excluded. 
The reasons for exclusion were (a) not diagnosed by a rheumatologist (n = 8), (b) older than 65 years (n = 2), 
and (c) suffering from a psychiatric disorder (schizophrenia; n = 1) or severe medical disorder (lupus; n = 2). Six 
patients refused to participate. Of the 64 participants who were eligible and randomly allocated to a treatment 
group, 23 were assigned to ABCT and 19 to relaxation (22 participants were assigned to the ‘mindfulness + amyg-
dala retraining’ group, the results of which will be reported elsewhere). The measurement completion rate was 
high, with 34 (81.0%) participants completing all of the biomarker outcomes. Eight participants dropped out 
of the study (4 in the ABCT group: 1 patient decision, 1 lack of efficacy, 1 low-grade adverse effect, 1 blood 
not drawn; and 4 in the relaxation group: 1 patient decision, 2 lack of efficacy, 1 blood not drawn). Therefore, 
a total of 19 (82.6%) participants in the ABCT, and 15 (78.9%) in the relaxation group completed the study 
(Fisher’s test, p = 0.999) and were included and analysed as they were originally assigned. The number of sessions 
attended, including the booster reminder assistances, was similar between groups (ABCT: Median = 10 sessions; 
Q1–Q3 = 8–11; relaxation: Median = 11 sessions; Q1–Q3 = 10–11; Z = 1.12; p = 0.302). All participants who were 
included in the analyses completed >50% of sessions, and 33 participants (97.1%) completed ≥75% of sessions. 
There were no differences between groups in terms of either credibility (ABCT: Median = 8; Q1–Q3 = 8 ‒ 8; relax-
ation: Median = 8; Q1–Q3 = 7‒8; Z = 0.88; p = 0.515), or treatment preference [ABCT group: ABCT = 4 (21.1%), 
relaxation = 2 (10.5%), other = 3 (15.8%), indifferent = 10 (52.6%); relaxation group: ABCT = 4 (26.7%), relaxa-
tion = 1 (6.7%), other = 3 (20.0%), indifferent = 7 (46.7%); Fisher test p = 0.956].
Although participants agreed not to change the dosage of any prescribed medication during the study period, 
we detected a pre-post variation in the frequency of opioid consumption: pre-ABCT = 8 (42.1%), post-ABCT = 6 
(31.6%); pre-relaxation = 3 (20.5%), post-relaxation = 5 (33.3%). We applied Fisher’s exact test at pre- and 
post-test, with a result of p = 0.271 and p = 0.999 respectively, and thus the two groups were rather similar with 
regard to the number of opiate users. All but one opioid user (who used Fentanyl) were users of Tramadol. Opioid 
consumption (in mg) remained very similar in each group: a) the Mann-Whitney U test showed no significant 
differences in opioid consumption between groups either at pre-test (ABCT vs relaxation, Z = −1.23, p = 0.319) 
or at post-test (ABCT vs relaxation, Z = −0.15, p = 0.918), and the Wilcoxon test showed no significant differ-
ences between the pre-post ABCT group consumption (Z = −1.61; p = 0.110) and in the pre-post relaxation 
group consumption (Z =<0.01; p = 0.999). The Mann-Whitney U test for comparing the two groups on the 
delta-values (post‒pre) for opioid consumption showed non-statistically significant values (Z = −1.51, p = 0.319). 
Thus, the two groups were rather similar with regard to the number of opiate users and the amount of opiate 
consumption in mg at each time point.
Effect of ABCT vs relaxation on FM functional status. The non-parametric Mann-Whitney U test 
on the FIQ delta-values showed significant differences between-groups at post-test (Z = −3.28; p = 0.001) and 
Figure 1. Generic path diagram of a mediation/moderation within-subjects model*. *From the proposal of 
Judd, Kenny and McClelland (2001) and the development of Montoya and Hayes (2017). The independent 
variable is the repeated-measures factor (“X”). M1 is the pre-post difference (mediating effect). M2 is the pre-
post sum (moderating effect). The FM functional status pre-follow up difference is the dependent variable (Y). 
“a x b” = indirect effect. c′ = direct effect after adjusting for the mediating effect. d = moderating effect.
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follow-up (Z = −2.48; p = 0.012). There was a significant ‘group x time’ interaction (RM ANOVA: F(2,30) = 9.12; 
p = 0.001; ƞ2 = 0.38), with decreases in the FIQ favouring the ABCT condition at post-test (ANCOVA: F (1, 
31) = 14.51; p = 0.001; ƞ2 = 0.32) and follow up (ANCOVA: F (1, 30) = 8.41; p = 0.007; ƞ2 = 0.22) [ABCT: pre-test 
Mn = 67.31 (SD = 17.17), post-test Mn = 43.11 (SD = 10.43), follow up Mn = 49.38 (SD = 15.44); relaxation: 
pre-test Mn = 59.60 (SD = 18.89), post-test Mn = 61.00 (SD = 25.78); follow-up Mn = 66.72 (SD = 17.90)].
Effect of ABCT vs relaxation on BDNF and inflammatory biomarkers. As seen in Table 2, the 
non-parametric Mann-Whitney U test on the raw (non-transformed) delta-values showed significant differ-
ences between-groups at post-test in BDNF (Z = −3.94; p < 0.001), GI composite (Z = −2.34; p = 0.019), and 
CRP (Z = −2.69; p = 0.006). In addition, significant ‘group x time’ interactions (RM ANOVA) were observed 
for BDNF (F (1, 32) = 24.67; p < 0.001) with large effects (ƞ2 = 0.44); GI composite (F (1, 32) = 5.29; p = 0.028) with 
large effects (ƞ2 = 0.14); and CRP (F (1, 32) = 4.67; p = 0.038) with moderately large effects (ƞ2 = 0.13), all of them 
showing decreases in the ABCT group. However, no significant ‘group x time’ interactions for IL-6 (F (1, 32) = 0.18; 
p = 0.675; ƞ2 = 0.01), TNF-α (F (1, 32) = 1.26; p = 0.269; ƞ2 = 0.04) and IL-10 (F (1, 32) = 0.03; p = 0.875; ƞ2  = < 0.01) 
were found. These results were also replicated using ANCOVAs at post-test after controlling for baseline scores 
(Table 2). Figure 3 is a graphic representation of the effects of ABCT vs relaxation on BDNF and low-grade 
inflammatory biomarkers.
Mediating and moderating effects of biomarkers on FM functional status. When the FM func-
tional status pre‒follow up difference was regressed on the pre‒post biomarker difference (i.e. mediating effect) 
and sum (i.e. moderating effect), we observed that the BDNF difference was a significant predictor of the FM 
functional status (β = 0.49, t = 3.08, p = 0.004), with significant explanatory power (R2 = 0.24; F(2,30) = 4.81; 
p = 0.015). The GI composite difference was a significant predictor of the FM functional status (β = 0.39, t = 2.27, 
p = 0.031) with an explanatory power trend (R2 = 0.15; F(2,30) = 2.57; p = 0.094), and the CRP difference was a 
significant predictor of the FM functional status (β = 0.55, t = 3.39, p = 0.002) with a significant explanatory 
Figure 2. Flowchart of the study. *For space reasons, the results of the “Mindfulness + Insula Retraining” arm 
will be detailed elsewhere.
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Outcomes
ABCT (n = 19) Relaxation (n = 15)
Mann-Whitney 
U test RM ANOVA ANCOVA
Mn (SD) Δ% Mn (SD) Δ% Z p F(df) p ƞ2 F(df) p ƞ2
BDNF (ng/ml)
  Pre 23.03 (6.65) 19.78 (6.89)
  Post 16.34 (5.02) −29.1 22.80 (4.69) 15.2 −3.94 <0001 24.68(1,32) <0001 0.44 28.81(1,31) <0001 0.48
GI composite*
  Pre 3.70 (1.40) 3.56 (1.39)
  Post 3.12 (1.18) −15.7 3.75 (1.20) 5.3 −2.34 0.019 5.29(1,32) 0.028 0.14 6.28(1,31) 0.018 0.17
CRP (pg/ml)
  Pre 5.60 (7.95) 3.46 (4.42)
  Post 2.89 (2.56) −48.4 4.07 (4.19) 17.6 −2.69 0.006 4.67(1,32) 0.038 0.13 4.63(1,31) .039 0.13
IL-6 (pg/ml)
  Pre 2.90 (1.56) 3.18 (1.19)
  Post 2.39 (0.70) −17.6 3.13 (1.60) −1.6 −0.47 0.656 0.18(1,32) 0.675 0.01 2.90(1,31) 0.098 0.09
TNF-α (pg/ml)
  Pre 6.05 (2.75) 6.10 (2.87)
  Post 5.61 (4.33) −7.3 6.23 (4.09) 2.1 −1.03 0.319 1.26(1,32) 0.269 0.04 1.26(1,31) 0.271 0.04
IL-10 (pg/ml)
  Pre 5.15 (0.41) 5.14 (0.46)
  Post 5.41 (0.86) 5.1 5.34 (0.59) 3.9 −0.37 0.758 0.03(1,32) 0.875 <001 0.02(1,31) 0.881 <0.01
Table 2. Between-group analyses on levels of biomarkers. Mn: mean. SD: standard deviation. Δ%: percentage 
increment. Z: Z-value. p: p-value. F: Snedecor’s F. ƞ2: partial eta squared as an effect size measure. Mann-
Whitney U test: Non-parametric Mann-Whitney U test on the raw (non-normalized) delta-values for the 
biomarkers (post-pre values), except for the GI composite, which was calculated by adding the Z scores for the 
normalized IL-6, TNF-α and CRP values. RM ANOVA: Repeated measures analysis of variance with pre- and 
post-treatment measures. ANCOVA: analysis of covariance at post-treatment with the baseline measure as a 
covariate. ANOVA and ANCOVA analyses were performed on log values (except for the BDNF). *Descriptive 
values are presented as raw scores except for the GI composite, which is a natural logarithm normalization sum.
Figure 3. Effects of ABCT vs. Relaxation on BDNF and inflammatory biomarkers. Note: Graphics are violin 
plots. The scales are different in different sections to make them legible (ng/ml in BDNF; pg/ml in CRP, IL-6, 
TNF-α and IL-10; and a natural logarithm normalization sum in the GI composite). Raw data was used in all 
measures (except for the GI Composite, which was calculated by adding the Z scores for the normalized log 
transformed IL-6, TNF-α and CRP values) to provide a more informed visualization of the treatment effects. 
*p < 0.05. **p < 0.01. ***p < 0.001.
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power (R2 = 0.28; F(2,30) = 5.85; p = 0.007). No other effects of biomarkers on FM functional status were observed 
(Table 3). The stepwise regression analyses showed that both BDNF pre‒post change scores (β = 0.40; t = 2.75, 
p = 0.010) and CRP pre‒post change scores (β = 0.39; t = 2.69, p = 0.011) significantly explained the FM func-
tional status pre‒follow up difference (R2 = 0.39; F(2,30) = 9.60; p = 0.001), with no indications of collinearity 
(T = 0.95; FIV = 1.05).
However, only BDNF showed significant indirect effects on FM functional status after calculating mediation/
moderation path analyses (Table 3). It was observed that the repeated-measures factor (“X”) indirectly influenced 
the change in FM functional status at follow-up through its effects on BDNF pre‒post change scores. Participants 
at post-test exhibited improvements in BDNF (a = 2.81; p = 0.031), and this improvement in BDNF predicted an 
improvement in FM functional status at follow-up (b = 1.87; p = 0.004). A bias-corrected bootstrap confidence 
interval for the indirect effect (a x b = 5.24) based on 10,000 bootstrap samples was entirely above zero (95% 
CI = 0.24–12.25). There was no evidence that the repeated-measures factor influenced the change in FM functional 
status independent of its effects on BDNF (c′ = 1.90; t = 0.42, p = 0.680). In other words, the residual FM functional 
status pre‒follow up difference that was over and above the mediating effect (i.e. after centring the biomarker sum) 
was not significant, but the intercept was not completely null, and, therefore, partial mediation was suggested61.
Discussion
Through the present pilot study, we have seen that the ABCT regimen of exercises managed to reduce FM func-
tional impairment as well as levels of GI composite and CRP marker in FM patients compared to an active control 
condition based on relaxation practices with large effects. Interestingly, we found that reductions in GI composite 
and CRP inflammatory marker were significantly related and subsequently followed by a relief in the severity of 
Biomarkers R2 F(df) pa
Direct Effects Indirect Effects
path Coeff. SE t pb path Boot. SE 95% CI
BDNF 0.24 4.81(2, 30) 0.015 a 2.81 1.24 2.26 0.031 a x b 5.24 3.48
0.24 to 
13.68
b 1.87 0.61 3.08 0.004
c′ 1.90 4.56 0.42 0.680
d −0.02 0.84 −0.02 0.983
GI-comp 0.15 2.57 (2, 30) 0.094 a 0.27 0.18 1.48 0.148 a x b 2.70 2.36
−0.98 to 
8.27
b 10.07 4.45 2.27 0.031
c′ 4.44 4.65 0.96 0.347
d −1.48 3.85 −0.39 0.703
CRP 0.28 5.85 (2, 30) 0.007 a 0.06 0.15 0.41 0.685 a x b 1.05 2.56
−5.53 to 
4.97
b 17.56 5.18 3.39 0.002
c′ 6.09 4.13 1.47 0.151
d −6.10 4.48 −1.36 0.183
IL-6 0.02 0.27 (2, 30) 0.768 a 0.12 0.09 1.45 0.158 a x b −0.26 1.80
−3.15 to 
4.21
b −2.12 10.09 −0.21 0.835
c′ 7.40 4.97 1.49 0.147
d 13.15 18.32 0.72 0.479
TNF-α 0.01 0.09 (2, 30) 0.912 a 0.09 0.05 1.77 0.085 a x b 0.14 2.30
−3.39 to 
6.22
b 1.62 19.60 0.08 0.935
c′ 7.00 5.13 1.37 0.182
d 5.96 14.30 0.42 0.680
IL-10 0.03 0.49 (2, 30) 0.617 a −0.04 0.02 −2.00 0.054 a x b 1.27 2.97
−4.70 to 
6.05
b −36.19 60.62 −0.60 0.555
c′ 5.87 5.23 1.12 0.271
d 17.16 65.43 0.26 0.795
Table 3. Direct and bootstrap indirect effects in the mediation/moderation models of biomarkers in FM 
functional status BDNF, GI-comp, CRP, IL-6, TNF-α and IL-10 difference scores were calculated as pre-post 
change scores (FIQ difference scores are pre-follow up change scores). Path coefficients are unstandardized 
ordinary least squares (OLS)-based regression coefficients. R2: determination coefficient (variance explained by 
regression models). F: Snedecor’s F associated with the adjustment of the regression model by using ANOVA. 
Coeff: unstandardized slope. t: Student’s t associated with the unstandardized slope by using the Wald test. SE: 
standard error. pa: p-value related to F-test. pb: p-value related to t-test. Boot: bootstrapped indirect effects using 
10,000 samples. 95% CI: 95% confidence interval. “a x b” = indirect effects. c′ = direct effects adjusted by the 
mediating effect. d = moderating effect (see Fig. 2).
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FM symptoms, meaning that reductions in the levels of those biomarkers that are theoretically pro-inflammatory8 
might work as mechanisms of change, facilitating improvements in FM functional status. However, both CRP and 
GI composite showed non-significant total indirect effects, maybe as a result of considering the total group as a 
whole to gain statistical power but at the cost of losing treatment specificity. Other RCTs evaluating the effects 
of mindfulness exercises on markers of inflammation found no significant reductions in healthy dementia car-
egivers62, but they found trends in university workers at risk for cardiovascular disease28 and in lonely elderly27. It 
has been suggested that inflammation biomarkers are more likely to be reduced by mind-body therapies such as 
meditation when they are implemented in populations with disease conditions rather than in healthy persons63. 
However, Rosenkranz et al.29 and Pace et al.64 found that mindfulness and compassion practices respectively 
reduced stress-induced immune and behavioural responses in healthy volunteers, and it was possibly through 
reduced stress reactivity learned through meditation exercises.
The biological pathways through which meditation could exert its benefits are not fully known, but they seem 
to include common and dissociable neural patterns with a relaxation response65. Considering that meditation may 
influence neural regions that might indirectly regulate stress66 ‒ including the hypothalamic-pituitary-adrenal 
axis (HPA)67 ‒ that the HPA might determine the production and inhibition of pro-inflammatory cytokines62 
and that some of the pro-inflammatory cytokines are in turn potent activators of the HPA axis68, the idea that 
inflammatory responses could mediate changes related to the regulation of emotional and affective responses to 
stress, thereby inducing reductions in disease symptoms, seems to be plausible69. However, we cannot overlook 
the fact that inflammatory biomarkers are complex to analyse, as the variability among these molecules is linked 
to a very large number of components, ranging from behavioural to environmental and emotional to biological or 
medical factors. Moreover, we only evaluated three cytokines (IL-6, TNF-α, IL-10) and a non-specific inflamma-
tory marker (CRP) as potential inflammatory biomarkers, even though there are plenty more molecules playing 
similar roles and interfering in the same processes already referenced12,70. In addition, we also let the patients keep 
their TAU, assuming that around half of them were taking antidepressants that are well-known to interact with 
the inflammatory system71. Even though we knew this was a risk that could alter results, we preferred to take it in 
order to provide this study with maximum external validity.
On the other hand, we have also observed that the ABCT treatment caused significant reductions in the 
BDNF levels of FM patients compared to the active control condition, which was based on relaxation exercises, 
with large effects. In addition, it was observed that reductions in BDNF were significantly related and followed 
by a decrease in FM functional impairment, showing significant indirect effects, which means that reductions in 
BDNF might function as an important ‒ but partial ‒ mechanism facilitating improvements in FM functional 
status. Several studies have suggested that FM and other central sensitivity syndromes present not only with 
elevated levels of general chronic inflammation but also with abnormalities in biomarkers related to neuronal 
plasticity, such as BDNF7,72. The BDNF baseline levels of the FM patients included in the present study were simi-
lar to those obtained in a previous study with patients suffering from central sensitivity syndrome with persistent 
somatic or visceral nociception72. Interestingly, the BDNF levels of the ABCT group at post-test approached 
those of pain-free controls in the referenced study72, being that all of the BDNF values obtained in the present 
study fell within the range of possible values in human serum73. Although BDNF is generally known to have a 
neuroprotective role, circulating levels of BDNF have been found to be significantly elevated in FM compared 
with healthy controls18, although their associations with the patients’ clinical complaints remains elusive16,71 and 
some studies have found no differences between FM patients and healthy controls74. Nevertheless, similar results 
to those obtained in our work were reported in a study in which BDNF levels decreased after a 2-week thermal 
therapy programme, with significant pre‒post treatment decreases in BDNF accompanied by benefits in the 
general health status75.
In a previous study, ABCT demonstrated more efficacy than relaxation techniques for reducing FM clinical 
symptomatology26. The results of the present work extend those previous findings by analysing changes in the 
BDNF and inflammation biomarkers as a result of those interventions. However, we must bear in mind that this 
was a secondary analysis of a RCT, with the limitation that it had a small sample size on which several compari-
sons were explored, thereby increasing the possibility of type-I and type-II errors. In addition, although there were 
no statistically significant between-group differences in opioid consumption at baseline or post-test assessments, 
an opposite evolution in the number of consumers was observed throughout the RCT. The ABCT group reduced 
opioid consumption whereas the relaxation group increased consumption. This result, although non-significant, 
should not be overlooked, because opioids have well-known effects on the endocrine and immune systems. It has 
been observed using animal models that pain syndromes modulate activity in endogenous pain control circuits, 
and this effect is sympatho-adrenal-dependent76; opiate receptor antagonists, such as naloxone, alter pain-related 
effects of BDNF77; and chronic tramadol administration (an opioid for treating moderate to severe pain that was 
used the most by opioid consumers in our sample) can produce neurotoxic effects via inflammation increases, 
implicating cytokines such as IL-6 and TNF-α78. Epidemiological studies suggest there is a reciprocal interaction 
between the immune system and endogenous as well as exogenous opioids, but RCTs are needed to elucidate the 
specific role of the opioid-immune system interaction in patients to determine its clinical relevance79. It has also 
been observed that opiate consumption may produce neurotoxicity, modifying epigenetic processes that may be 
associated with peripheral alterations of BDNF, but the clinical implications of those changes are not clear, and 
more investigation is necessary80. Thus, in absence of clear hypotheses, future studies should investigate how 
opioid consumption might alter the modulation of endogenous pain control circuits and the production and 
pain-related effects of pro-inflammatory cytokines and BDNF in FM patients. Finally, we only conducted one 
blood collection at pre- and at post-treatment. Therefore, future research should use higher-powered designs, 
primarily aimed at assessing biomarker behaviour in FM patients to reduce possible errors related to multiple 
comparisons, by performing measurements on two sets of samples (e.g. serum and plasma) and ideally using 
two different methods (e.g. investigation of gene expression and protein levels), as is usually recommended12,81.
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To the best of our knowledge, this is the first study to evaluate neurotrophic and inflammatory changes asso-
ciated with the ABCT application in patients with FM. Thus, the results obtained in the present pilot RCT might 
serve as a heuristic force to conduct future studies of this third-wave psychological intervention, moving forward 
in a promising area of research. The enormous heterogeneity in the neurotrophic response and inflammatory 
systems adds special challenges to this area. That said, in summation, this preliminary work leads us to suggest 
that, as hypothesized, neurotrophic factor and inflammation levels seem to be reduced by the ABCT exercises in 
FM patients and that they might be mechanisms of FM functional status improvement. These findings are in line 
with both the idea that alterations in central nervous system nociceptive processing are present in people with 
FM and that a potential mechanism might include a peripheral nervous system component associated with the 
generation of pain, with a possible role of systemic inflammation6,69. Contrary to previous proposals that intended 
to explain the heterogeneity of FM clinical responses by conferring a moderating role to inflammatory biomark-
ers20,54, we did not find that role for either BDNF or the inflammatory markers used in the present work. In this 
sense, it has also been pointed out that some of the heterogeneous responses to FM treatment could be due to 
differences in the predominance of the referenced mechanisms underlying a peripherally driven pain condition 
involving low-grade systemic inflammation or to alterations of the central nervous system involved in nociceptive 
pain processing6,69.
A general hypothesis that could frame our findings may be that ABCT takes root in a motivational system 
that encourages an individual to re-contextualize their life by accepting their circumstances and by improving 
their attachment style and positive and compassionate engagement with specific aspects of their life. This may be 
achieved through awareness and clarification of personal values in family, social relationships, work, and personal 
development26,31. All of this might, in turn, reduce the impact of psychological factors that provoke stress and 
emotional reactivity and enhance the pain experience, thereby benefiting the regulation of BDNF and inflam-
matory status, stimulating commitment to valued actions, and favouring an improvement in FM health status 
and symptomatology82. Nevertheless, future research with higher-powered designs should investigate the specific 
sequence of these events as well as whether changes in mindfulness, self-compassion and psychological flexibility, 
on the one hand, and neurotrophic and inflammatory responses as well as FM symptoms, on the other hand, are 
conditioned and linked to each other as a result of the ABCT practices.
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